United States securities and exchange commission logo





                            August 31, 2021

       Thomas Kim
       Chief Executive Officer
       Enfusion, Inc.
       125 South Clark Street, Suite 750
       Chicago, IL 60603

                                                        Re: Enfusion, Inc.
                                                            Amendment No. 1 to
Draft Registration Statement on Form S-1
                                                            Submitted August
18, 2021
                                                            CIK No. 0001868912

       Dear Mr. Kim:

             We have reviewed your amended draft registration statement and
have the following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional
       comments. References to prior comments refer to comments in our July 28,
2021 letter.

       Amendment No. 1 to Draft Registration Statement on Form S-1 submitted
August 18, 2021

       Summary Consolidated Financial and Other Data, page 14

   1.                                                   Please revise to
include summary consolidated statement of operations information for the
                                                        June 30 interim
periods.
       Management's Discussion and Analysis of Financial Condition and Results
of Operations
       Key Metrics and Other Non-GAAP Financial Measures, page 71

   2.                                                   We note your response
to prior comment 12. Please revise your discussion of the non-
                                                        GAAP measures to
explain further the adjustment for management incentive award
                                                        payments and why such
amounts are excluded from your non-GAAP measures as
                                                        provided in your
response. Also, your response indicates that the Award Unit repurchases
 Thomas Kim
Enfusion, Inc.
August 31, 2021
Page 2
      were made upon entry into a Credit Agreement with Silicon Valley Bank and
the issuance
      of Class D units, however, your revised disclosures in Note 10 indicate
such repurchases
      were made in association with the Class C-2 unit issuance in fiscal 2019
and Class D unit
      issuance in fiscal 2020. Please explain this apparent inconsistency and
revise your
      disclosures as necessary.
Note 10. Management Incentive Plans, page F-21

3.    We note your response to prior comment 18. Please explain in reasonable
detail why you
      made the discretionary election to repurchase certain Award Units in
conjunction with the
      issuance of Class C-2 and Class D Preferred Units and tell us which
employees
      participated in such repurchases. Also, we note from your response to
prior comment 12
      that you repurchased additional Award Units in June 2021 as part of a
negotiated
      separation agreement. Please revise your interim period notes to include
a discussion of
      such repurchase, including the number of units, repurchase price and and
related
      compensation expense.
Unaudited Condensed Consolidated Financial Statements of Enfusion Ltd. LLC
Notes to Condensed Consolidated Financial Statements, page F-28

4.    Please revise to disclose the date through which subsequent events have
been evaluated
      and state whether such date is the date the financial statements were
issued or available to
      be issued. Refer to ASC 855-10-50-1.
General

5.    We note you include adjusted revenue churn and adjusted EBITDA margin in
the
      graphics. Please revise to also disclose revenue churn for a more
balanced presentation of
      customer attrition. Also, disclose the most directly comparable GAAP
measure with
      equal or greater prominence to the non-GAAP measure of adjusted EBITDA
margin.
      Refer to Question 102.10 of the non-GAAP C&DIs.
        You may contact David Edgar, Senior Staff Accountant, at (202) 551-3459
or Kathleen
Collins, Accounting Branch Chief, at (202) 551-3499 if you have questions
regarding comments
on the financial statements and related matters. Please contact Mitchell
Austin, Staff
Attorney, at (202) 551-3574 or Jan Woo, Legal Branch Chief, at (202) 551-3453
with any other
questions.



                                                            Sincerely,
FirstName LastNameThomas Kim
                                                            Division of
Corporation Finance
Comapany NameEnfusion, Inc.
                                                            Office of
Technology
August 31, 2021 Page 2
cc:       Gregg L. Katz, Esq.
FirstName LastName